

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of Chronic Obstructive Lung Disease among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on Chronic Obstructive Lung Disease, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on Chronic Obstructive Lung Disease research.

The purpose of this document is to safeguard the interests of all GOLD collaborators by an open disclosure of interests.

GOLD Structure

At present, the GOLD program is conducted through a GOLD Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GOLD documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GOLD. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GOLD website after completion.

Definitions:

- 1. Grants :** refers to any grant paid to your organization.
- 2. Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from

which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.

3. *Shares:* refers to any shares in Chronic Obstructive Lung Disease-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/children). The company is to be listed, not the number of shares.

4. *Non-financial support:* In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced Chronic Obstructive Lung Disease-related commercial organizations can be involved in their dissemination and audit, including support for publications.

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name:

Member of:

Are there any relevant financial interests to disclose? (Yes or No in each box)

| Name of Entity | Grant? | Personal Fee? | Non-Financial Support? | Other? | Comments: |
|-----------------------|---------------|----------------------|-------------------------------|---------------|------------------|
| Astra Zeneca | yes | yes | no | no | |
| Boehringer Ingelheim | Yes | Yes | No | No | |
| Chiesi | Yes | Yes | No | No | |
| GlaxoSmithKline | Yes | Yes | No | No | |
| Grifols | Yes | Yes | No | No | |
| Mundipharma | Yes | Yes | No | No | |
| Novartis | Yes | Yes | No | No | |
| Takeda | Yes | Yes | No | No | |
| Menarini | No | Yes | No | No | |
| CSL Behring | No | Yes | No | No | |
| Bayer Schering AG | Yes | No | No | No | |
| MSD | Yes | No | No | No | |
| Pfizer | Yes | No | No | no | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |